Health state utilities associated with migraine treatment estimated from a general population sample may be used to represent route of administration and adverse events (AEs) in cost-utility models, a new study found. In time trade-off interviews, patients with migraine and general population participants in the United Kingdom valued health state vignettes based on literature, medication labels, and clinician interviews. All respondents valued migraine health states varying in route of administration. Researchers found:
- A total of 400 participants completed interviews (200 general population, 200 migraine patients).
- In the general population sample, mean utilities of health states without aura were 0.79 with daily oral medication, 0.78 with 1 injection per month, and 0.72 with between 31 and 39 injections once every 3 months.
- The greatest disutilities were for AEs associated with oral medications.
Matza LS, et al. Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. [Published online ahead of print March 28, 2019]. Qual Life Res . doi: 10.1007/s11136-019-02163-3.